SANTA CLARA, Calif. - (Business Wire) XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentations at the following upcoming conferences:
| | -- | | Baird's 2008 Growth Stock Conference |
| | | Wednesday, May 14 at 9:20 a.m. Eastern Time |
| -- | | Citi 2008 Global Healthcare Conference |
| | | Thursday, May 22 at 3:30 p.m. Eastern Time |
To access the live presentations via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.
A replay of each Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the respective live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. Its development and commercialization efforts are currently focused on potential treatments of central nervous system disorders. XP13512, also known as Solzira™ in the U.S. market, is XenoPort’s most advanced product candidate. It has successfully completed three pivotal trials in its Phase 3 clinical program for the treatment of moderate-to-severe primary restless legs syndrome, and has successfully completed a Phase 2a clinical trial for the management of post-herpetic neurolgia. XenoPort has also reported positive results from a Phase 2a clinical trial of its second product candidate, XP19986, in patients with gastroesophageal reflux disease. XenoPort has also reported positive results from a Phase 1 clinical trial of its third product candidate, XP21279, which is being developed as a potential treatment for Parkinson’s disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered U.S. trademark. Solzira is a U.S. trademark of GlaxoSmithKline.
XNPT2G
XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
